In this issue:
Increased risk of no biopsy after abnormal mammography for Black, Asian & Hispanic women
Characteristics & disease outcomes in ERBB2-low vs. ERBB2-0 breast cancer
Prognostic significance of HER2-low vs. HER2-zero in node-negative breast cancer
Physical activity, neoadjuvant chemo completion & pCR
Atezolizumab in high-risk, HER2- positive early breast cancer
Survival after breast cancer with subsequent live birth
Long-term outcomes of palbociclib + fulvestrant vs. placebo + fulvestrant in hormone receptor-positive/HER2- negative advanced breast cancer
Food intake and diarrhoea with abemaciclib
Neoadjuvant letrozole, PEPI & recurrence free survival in postmenopausal early-stage strongly ER-positive/HER2-negative breast cancer
BMI & efficacy/tolerability of full-weight-based paclitaxel chemo in early breast cancer
Please login below to download this issue (PDF)